general news

Mobidiag receives emergency use authorization for its Novodiag® system

Mobidiag receives emergency use authorization for its Novodiag® system
Mobidiag receives emergency use authorization for its Novodiag® system

As the coronavirus outbreak has considerably increased the demand for testing kits, leading healthcare companies worldwide have responded quickly by introducing cutting-edge testing methods. Adhering to the same principle, Mobidiag Ltd., a molecular diagnostic company developing advanced solutions to progress diagnosis of infectious diseases, has reportedly received emergency use authorization in Finland for its Novodiag® molecular diagnostic testing system for COVID-19.

As per sources, this testing method facilitates quick and fully automated detection of the coronavirus. The test will work using the Novodiag quick ‘sample-in, result-out’ system, enabling the fully automated detection of SARC-COV-2 in around 1 hour.

Moreover, Novodiag® has a closed system that safeguards healthcare professionals and laboratory staff members from possible contamination. Due to its user-friendly nature, this system can also be used in hard to reach and high-risk areas without the need for highly trained professionals.

This new testing system complements Amplidiag® COVID-19, which is an emergency use testing system rendered appropriate for high-throughput screening. Introduced on 14 April 2020, this test has been routinely used in Finland as well as France.

Tuomas Tenkanen, CEO at Mobidiag said that the coronavirus outbreak is a global challenge that needs all parts of the industry to reply with cutting-edge solutions for multiple settings. Early-stage detection of COVID-19 disease is a vital step in aiding clinical decisions to proficiently manage epidemiological as well as infection control measures to quarantine patients on time and improve patient care, Tenkanen claimed.

Mr. Tenkanen added that the company has leveraged its current technologies and expertise, including manufacturing and supply chain management, to develop 2 coronavirus diagnostics tests, delivering solutions to clinicians suitable for their laboratory capacities. The company is delighted to offer Novodiag® COVID-19 which can be used without the need for trained professionals and can be used in the smaller unit and Amplidiag® COVID-19 systems which can be used for high-throughput testing in larger testing.

The process for getting emergency use authorization for Novodiag® molecular diagnostic testing is still on-going in the UK, Sweden, UK, and France.


Source Credit -

About the author

Bhushan Tambe

A qualified computer graduate, Bhushan Tambe always nurtured a passion for words. Post his education, he decided to transform his penchant of penning down poetry and stories into a full-time career. Presently, Bhushan writes numerous articles for and a few other websites, on subjects spanning business, finance, and the like.